Pfizer wins FDA approval for 'first and only' oral treatment for prostate cancer drug

Pfizer Inc. confirmed that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application to treat prostate cancer. The New York-based pharma giant, which opened Tuesday morning at $39.46 a share, created the new cancer drug with Japan-based Astellas Pharma Inc. The treatment, Xtandi, helps patients with metastatic hormone-sensitive prostate cancer (mCSPC). This type of prostate cancer spreads to other parts o f the body. In 2019, it is estimated that just over 40,000…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news